Site-dependent biological activity of valinomycin analogs bearing derivatizable hydroxyl sites

Journal of Peptide Science

Volumn 19, Issue 12, 2013, Pages 751-757

  Annese, Cosimo ^a,b   Abbrescia, Daniela I ^a   Catucci, Lucia ^a   D'Accolti, Lucia ^a,b   Denora, Nunzio ^a   Fanizza, Immacolata ^a   Fusco, Caterina ^b   La Piana, Gianluigi ^a  

^a UNIVERSITY OF BARI   (Italy)

^b CNR   (Italy)

Author keywords

cyclic depsipeptide; hydroxylation; ionophore; mitochondria; mitochondrial membrane potential; natural compound; valinomycin

Indexed keywords

CESIUM; HYDROXYL GROUP; METHANOL; POTASSIUM ION; SODIUM ION; SUCCINATE DEHYDROGENASE; VALINOMYCIN DERIVATIVE;

ANIMAL CELL; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DERIVATIZATION; DRUG BINDING; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; HYDROXYLATION; IC 50; LIVER MITOCHONDRION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MITOCHONDRIAL VOLUME; MITOCHONDRION SWELLING; NONHUMAN; POTASSIUM TRANSPORT; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

MAMMALIA; RATTUS;

CYCLIC DEPSIPEPTIDE; HYDROXYLATION; IONOPHORE; MITOCHONDRIA; MITOCHONDRIAL MEMBRANE POTENTIAL; NATURAL COMPOUND; VALINOMYCIN;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG STABILITY; INHIBITORY CONCENTRATION 50; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA, LIVER; MITOCHONDRIAL SWELLING; OXYGEN CONSUMPTION; RATS; VALINOMYCIN;

EID: 84888060077     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.2571     Document Type: Article

References (27)

1. Ovchinnikov YA, Ivanov VT, Shkrob AM,. Membrane Active Complexones. Elsevier: Amsterdam, 1974.
2. Izatt RM, Bradshaw JS, Nielsen SA, Lamb JD, Christensen JJ, Sen D,. Thermodynamic and kinetic data for cation-macrocycle interaction. Chem. Rev. 1985; 85: 271-339.
3. Huczyński A,. Polyether ionophores-promising bioactive molecules for cancer therapy. Bioorg. Med. Chem. Lett. 2012; 22: 7002-7010.
4. Marjanovic̈ M, Kralj M, Supek F, Frkanec L, Piantanida I, Šmuc T, Tušek-Božic̈ L,. Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores. J. Med. Chem. 2007; 50: 1007-1018.
5. Lofrumento DD, La Piana G, Abbrescia DI, Palmitessa V, La Pesa V, Marzulli D, Lofrumento NE,. Valinomycin induced energy-dependent mitochondrial swelling, cytochrome c release, cytosolic NADH/cytochrome c oxidation and apoptosis. Apoptosis 2011; 16: 1004-1013.
6. Abdalah R, Wei L, Francis K, Yu SP,. Valinomycin-induced apoptosis in Chinese hamster ovary cells. Neurosci. Lett. 2006; 405: 68-73.
7. Paananen A, Järvinen K, Sareneva T, Salkinoja-Salonen MS, Timonen T, Hölttä E,. Valinomycin-induced apoptosis of human NK cells is predominantly caspase independent. Toxicology 2005; 212: 37-45.
8. Ryoo IJ, Park HR, Choo SJ, Hwang JH, Park YM, Bae KH, Shin-Ya K, Yoo ID,. Selective cytotoxic activity of valinomycin against HT-29 human colon carcinoma cells via down-regulation of GRP78. Biol. Pharm. Bull. 2006; 29: 817-820.
9. Cheng YQ,. Deciphering the biosynthetic codes for the potent anti-SARS-CoV cyclodepsipeptide valinomycin in Streptomyces tsusimaensis ATCC 15141. ChemBioChem 2006; 7: 471-477.
10. Trapani G, Denora N, Trapani A, Laquintana V,. Recent advances in ligand targeted therapy. J. Drug Targeting 2012; 20: 1-22.
11. Heller A, Brockhoff G, Goepferich A,. Targeting drugs to mitochondria. Eur. J. Pharm. Biopharm. 2012; 82: 1-18.
12. Vlahov IR, Leamon CP,. Engineering folate-drug conjugates to target cancer: from chemistry to clinic. Bioconjugate Chem. 2012; 23: 1357-1369.
13. nd ACS National Meeting, Denver, CO, August 28-September 1, 2011, American Chemical Society, Washington, DC, MEDI-57.
14. Annese C, D'Accolti L, De Zotti M, Fusco C, Toniolo C, Williard PG, Curci R,. Concerning selectivity in the oxidation of peptides by dioxiranes. Further insight into the effect of carbamate protecting groups. J. Org. Chem. 2010; 75: 4812-4816.
15. Annese C, Fanizza I, Calvano CD, D'Accolti L, Fusco C, Curci R, Williard PG,. Selective synthesis of hydroxy analogues of valinomycin using dioxiranes. Org. Lett. 2011; 13: 5096-5099.
16. Marzulli D, La Piana G, Cafagno L, Fransvea E, Lofrumento NE,. Proton translocation linked to the activity of the bi-trans-membrane electron transport chain. Arch. Biochem. Biophys. 1995; 319: 36-48.
17. La Piana G, Marzulli D, Gorgoglione V, Lofrumento NE,. Porin and cytochrome oxidase containing contact sites involved in the oxidation of cytosolic NADH. Arch. Biochem. Biophys. 2005; 436: 91-100.
18. La Piana G, Fransvea E, Marzulli D, Lofrumento NE,. Mitochondrial membrane potential supported by exogenous cytochrome c oxidation mimics the early stages of apoptosis. Biochem. Biophys. Res. Commun. 1998; 246: 556-561.
19. Akerman KEO, Wikström MKF,. Safranine as a probe of the mitochondrial membrane potential. FEBS Lett. 1976; 68: 191-197.
20. Fransvea E, La Piana G, Marzulli D, Lofrumento NE,. Inhibition by butylmalonate of proton influx in nonphosphorylating mitochondria. Arch. Biochem. Biophys. 1998; 355: 93-100.
21. Valeur B,. Molecular Fluorescence: Principles and Applications, Wiley-VCH: Weinheim, 2001; 339-343.
22. Teplova VV, Mikkola R, Tonshin AA, Saris NEL, Salkinoja-Salonen MS,. The higher toxicity of cereulide relative to valinomycin is due to its higher affinity for potassium at physiological plasma concentration. Toxicol. Appl. Pharmacol. 2006; 210: 39-46.
23. Tosteson DC, Cook P, Andreoli T, Tieffenberg M,. The effect of valinomycin on potassium and sodium permeability of HK and LK sheep red cells. J. Gen. Physiol. 1967; 50: 2513-2525.
24. Pressman BC,. Induced active transport of ions in mitochondria. Proc. Natl. Acad. Sci. U. S. A. 1965; 53: 1076-1083.
25. Duax WL, Griffin JF, Langs DA, Smith GD, Grochulski P, Pletnev V, Ivanov V,. Molecular structure and mechanisms of action of cyclic and linear ion transport antibiotics. Peptide Science 1996; 40: 141-155.
26. Ovchinnikov YA, Ivanov VT,. Integrated conformational studies of cyclopeptides. Tetrahedron 1974; 30: 1871-1890.
27. Wang F, Zhao C, Polavarapu PL,. A study of the conformations of valinomycin in solution phase. Biopolymers 2004; 75: 85-93.